Key result
ANTXR1 blockade with T8Ab cuts mortality ~49% and improves cardiac function in preclinical heart failure.
Why the study?
Heart disease urgently needs improved therapies, but clinical agents capable of interfering with cardiac fibrosis do not yet exist.
Does ANTXR1 blockade improve cardiac function and survival in preclinical models of heart failure?
Does ANTXR1 blockade improve cardiac function and survival in preclinical models of heart failure?
ANTXR1 blockade prevents and reverses cardiac dysfunction in preclinical models of ischemic, hypertensive, and obesity-induced heart failure by modulating cardiac fibroblast activation and collagen turnover.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ANTXR1 blockade in heart failure; leaves open translation to human therapy.
Heart disease, a leading cause of mortality worldwide, is in urgent need of improved therapies. Fibrosis, an accumulation of collagen-rich extracellular matrix in response to injury, is a hallmark of heart disease, but clinical agents that can interfere with the fibrotic pathway do not yet exist. Here we show that ANTXR1/TEM8, a pathology-induced transmembrane protein required for collagen removal, exacerbates injury in multiple models of heart failure. Genetic disruption of Antxr1 and treatment with human neutralizing antibodies prevented heart deterioration following acute myocardial infarction. ANTXR1 pharmacological blockade also improved heart function in models of pressure overload and obesity-induced heart disease with preserved ejection fraction. Improved heart function was accompanied by enhanced exercise tolerance. Mechanistic studies revealed an ANTXR1-antibody-driven improvement in post-infarct scar formation followed by attenuation of late-stage, chronic TGFβ-mediated extracellular matrix remodeling. Thus, ANTXR1-mediated collagen turnover during heart failure is both maladaptive and druggable, providing avenues for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Boccella et al. (2025) studied Heart failure. T8Ab (anti-ANTXR1 antibody) vs. Vehicle was evaluated on Survival post-myocardial infarction. ANTXR1 pharmacological blockade with T8Ab improved survival to 67% compared to 35% with vehicle and enhanced cardiac function in preclinical models of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: